Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

This study has been completed.
Information provided by:
Rigshospitalet, Denmark Identifier:
First received: February 1, 2006
Last updated: April 20, 2007
Last verified: April 2007

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Condition Intervention Phase
Drug: Combined treatment with Arimidex and Zoladex before IVF
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • size of endometriomas after 2½ month of combined downregulation

Estimated Enrollment: 20
Study Start Date: January 2005

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
  • Couples with indication and wish for IVF/ICSI
  • Age of women: 20-40 years
  • Regular menstrual cycle within normal range (21-35 days)
  • Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria:

  • History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
  • Treatment of endometriosis with GnRH agonist during the last 3 month
  Contacts and Locations
Please refer to this study by its identifier: NCT00286351

The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet
Copenhagen, Copenhagen East, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Principal Investigator: Kristine Lossl, medical doctor The Fertility Clinic, Copenhagen University Hospital Rigshospitalet
  More Information

No publications provided Identifier: NCT00286351     History of Changes
Other Study ID Numbers: endo 220604
Study First Received: February 1, 2006
Last Updated: April 20, 2007
Health Authority: Denmark: National Board of Health

Additional relevant MeSH terms:
Genital Diseases, Female
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 14, 2014